Find a Clinical Trial | Tufts Medicine

Filter

Showing 1 - 10 out of 14

Dompe' Reparixin study

A multinational, multicentre, randomised, doubleblinded, placebo-controlled, parallel-group phase III trial Reparixin 1200 mg three times a day as add-on therapy to standard of care to limit disease progression in hospitalised adult patients with COVID-19.

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

AN2 EBO301 MAC Study

A Phase 2/3, Randomized, Double-blind, Placebo-controlled, Multicenter, Prospective Study to Assess the Efficacy, Safety, and Pharmacokinetics of Orally Administered Epetraborole in Patients with Treatment-refractory Mycobacterium avium Complex Lung Disease (MACrO2)

Mycobacterial disease

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

Moderna mRNA 1273 study

A Phase 2/3, Two-Part, Open-Label, Dose-Escalation, Age De-escalation and Randomized, Observer-Blind, Placebo-Controlled Expansion Study to Evaluate the Safety, Tolerability, Reactogenicity, and Effectiveness of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Children 6 Months to Less Than 12 Years of Age

COVID-19

All genders

0-12

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

HGB-210

A Phase 3 Study Evaluating Gene Therapy by Transplantation of Autologous CD34+ Stem Cells Transduced Ex Vivo with the LentiGlobin BB305 Lentiviral Vector in Subjects with Sickle Cell Disease.

Sickle cell anemia

All genders

2-50

Recruiting now

Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center

Learn more

Letermovir for secondary prophylaxis for CMV disease in solid organ transplant recipients

A pilot trial of the tolerability and clinical effectiveness of letermovir when used for secondary prophylaxis to prevent recurrent cytomegalovirus disease in solid organ transplant recipients

Cytomegalovirus infection

All genders

18-75

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

ANHL1931

ANHL1931: A Randomized Phase 3 trial of Nivolumab in Combination with Chemo-immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-cell Lymphoma

Lymphoma

All genders

Recruiting now

Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center

Learn more

A Long COVID-19 Observational Pilot Study Using Wearable Devices

Detection and Risk Assessment in Post COVID-19 Infection – A Long COVID-19 Observational Pilot Study

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

COVID-19 Survivors Registry

National COVID-19 Survivors Registry

COVID-19

All genders

18+

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

Armata Bacteriophage Study; disArm Study

Phase 1b/2a, Randomized, Double-Blind, Placebo-Controlled, Multiple Ascending Dose Escalation Study of the Safety, Tolerability, and Efficacy of Intravenous AP-SA02 as an Adjunct to Best Available Antibiotic Therapy Compared to Best Available Antibiotic Therapy Alone for the Treatment of Adults With Bacteremia Due to Staphylococcus aureus.

Bacterial infection, Staphylococcus aureus

All genders

18-100

Recruiting now

Department of Medicine, Division of Geographic Medicine + Infectious Diseases

Learn more

ON-TRK

Prospective Non-interventional study in patients with locally advanced or metastatic TRK fusion cancer treated with larotrectinib

Solid tumors

All genders

No minimum age

Recruiting now

Department of Medicine, Department of Pediatrics, Division of Hematology/Oncology, Cancer Center

Learn more